Login to Your Account

Gemphire solid in small HoFH study, looks to shine in phase III

By Marie Powers
News Editor

Thursday, June 29, 2017

Enrollment in the phase IIb COBALT-1 trial of gemcabene was small, due to the orphan population of HoFH, but meaningful, according to Lee Golden, chief medical officer of Gemphire Therapeutics Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription